Ground News

News from Drug Discovery and Development

Stay current with all the latest and breaking news from Drug Discovery and Development. Compare headlines and media bias behind news outlets on stories breaking today.

We’ve discovered 56 headlines written by Drug Discovery and Development during the past 3 months.

Drug Discovery and Development’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Drug Discovery and Development’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Drug Discovery and Development

Where is Drug Discovery and Development located?Drug Discovery and Development's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Drug Discovery and Development News

Vaccines · United States

Kennedy's vaccine committee endorses preservative-free fall flu shots

49% Center coverage: 114 sources

The Advisory Committee on Immunization Practices (ACIP), recently remade by Health and Human Services Secretary Robert F. Kennedy Jr., voted Thursday in favor of only recommending flu shots that don’t contain the mercury-based preservative thimerosal. See the Story

Influenza · San Francisco

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

73% Center coverage: 11 sources

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for...See the Story

Alzheimer's Disease · United States

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s ...

Coverage: 2 sources

End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled See the Story

Korean team reveals all-in-one cancer nanomedicine in pre-clinical studies

Researchers at the Korea Research Institute of Standards and Science (KRISS) have created a new nanomaterial that can simultaneously detect and treat cancer using multiple approaches. In laboratory tests with mice, the gold-iron particles enabled real-time tumor imaging while delivering targeted treatment through heat, chemical reactions and immune system activation. Published in the Chemical Engineering… The post Korean team reports all-in-one …Cancer · South Korea Read Article

Why Cybin's CEO sees RFK Jr. and J&J's ketamine clinics as keys to clinical psilocybin's mainstream moment

From the Grateful Dead’s tour bus to the FDA’s approval queue, from “turn on, tune in, drop out” to potentially “take two doses and see me in a year,” this is the improbable journey of psychedelics in 2025. We now live in a world where a ketamine analog marketed by Johnson & Johnson could provide… The post Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment appeared first on Drug Discovery a…Robert F. Kennedy Jr. · United States Read Article

Genmab unveils striking new site near Princeton

Genmab, a Danish company focused on developing antibody therapies for patients with cancer, opened a new site in Plainsboro, NJ. The company was awarded $8.4 million in tax credits over seven years by the Murphy Administration to develop the new location. Expanding presence in NJ “Our extension at the Princeton Forrestal Center will strengthen our… The post As some biotechs cut, Genmab unveils striking new site near Princeton appeared first on …Cancer · New Jersey Read Article

OS Therapies announces favorable FDA feedback on clinical strategy for osteosarcoma drug

OS Therapies announced it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a mid-June Type D meeting. The development supports its plan to use an external control arm to support a Biologics Licensing Application (BLA) for its lead candidate, OST-HER2, a Listeria monocytogenes-based immuno-oncology asset originally developed by Advaxis… The post OS Therapies announces favorable FDA feedback on exte…United States · United States Read Article

AbbVie announces head-to-head results challenging migraine treatment status quo

For the more than one billion people worldwide living with migraine, the path to effective prevention can feel like an obstacle course. While some migraine patients struggle to find a formal diagnosis, others must navigate a lengthy trial-and-error process with outdated therapies before they can access treatments that provide real relief. Despite migraine ranking as… The post AbbVie announces head-to-head results challenging migraine treatment s…Read Article

GSK sees latest Nucala approval as the first shot in a long-term war to deconstruct and personalize COPD treatment - Drug Discovery and Development

Chronic obstructive pulmonary disease, a condition CDC estimates affects about 14.2 million (6.5%) U.S. adults, can be brutal. And for patients with COPD, exacerbations are an acute risk, a sudden flare-up where breathing becomes a potentially life-threatening struggle against inflamed airways. “Anecdotally… if I reflect back on some of my experiences in… emergency medicine departments… The post GSK sees latest Nucala approval as the first shot …United States · United States Read Article

Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

64% Center coverage: 40 sources

Pharma · United States See the Story

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)

100% Center coverage: 5 sources

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic autoimmune skin disorder. BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with underlying type 2 inflammation. The b…BP · United States See the Story

News from Drug Discovery and Development

News from Drug Discovery and Development

Information about Drug Discovery and Development

Media Bias Ratings

Factuality

Ownership

Top Drug Discovery and Development News

Kennedy's vaccine committee endorses preservative-free fall flu shots

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s ...

Korean team reveals all-in-one cancer nanomedicine in pre-clinical studies

Why Cybin's CEO sees RFK Jr. and J&J's ketamine clinics as keys to clinical psilocybin's mainstream moment

Genmab unveils striking new site near Princeton

OS Therapies announces favorable FDA feedback on clinical strategy for osteosarcoma drug

AbbVie announces head-to-head results challenging migraine treatment status quo

GSK sees latest Nucala approval as the first shot in a long-term war to deconstruct and personalize COPD treatment - Drug Discovery and Development

Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)

Similar News Topics

Topics Most Covered by Drug Discovery and Development

Sources Covering Similar Topics

Breaking News Topics Related to Drug Discovery and Development